AMPH
Income statement / Annual
Last year (2023), Amphastar Pharmaceuticals, Inc.'s total revenue was $644.40 M,
an increase of 29.14% from the previous year.
In 2023, Amphastar Pharmaceuticals, Inc.'s net income was $137.55 M.
See Amphastar Pharmaceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$644.40 M
|
$498.99 M
|
$437.77 M
|
$349.85 M
|
$322.36 M
|
$294.67 M
|
$240.18 M
|
$255.17 M
|
$251.52 M
|
$210.46 M
|
| Cost of Revenue |
$300.43 M |
$250.13 M |
$238.03 M |
$206.51 M |
$190.43 M |
$187.68 M |
$149.38 M |
$150.98 M |
$174.17 M |
$159.21 M |
| Gross Profit |
$343.97 M |
$248.86 M |
$199.74 M |
$143.34 M |
$131.92 M |
$106.99 M |
$90.80 M |
$104.19 M |
$77.35 M |
$51.26 M |
| Gross Profit Ratio |
0.53 |
0.5 |
0.46 |
0.41 |
0.41 |
0.36 |
0.38 |
0.41 |
0.31 |
0.24 |
| Research and Development
Expenses |
$73.74 M
|
$74.77 M
|
$60.93 M
|
$67.23 M
|
$68.85 M
|
$57.56 M
|
$43.42 M
|
$41.20 M
|
$37.07 M
|
$28.43 M
|
| General & Administrative
Expenses |
$51.54 M
|
$45.06 M
|
$51.43 M
|
$50.38 M
|
$50.28 M
|
$49.89 M
|
$44.46 M
|
$41.83 M
|
$41.50 M
|
$34.81 M
|
| Selling & Marketing
Expenses |
$28.85 M
|
$21.53 M
|
$17.49 M
|
$14.78 M
|
$12.83 M
|
$8.16 M
|
$6.46 M
|
$5.47 M
|
$5.47 M
|
$5.56 M
|
| Selling, General &
Administrative Expenses |
$80.39 M
|
$66.59 M
|
$68.92 M
|
$65.16 M
|
$63.11 M
|
$58.04 M
|
$50.92 M
|
$47.30 M
|
$46.97 M
|
$40.37 M
|
| Other Expenses |
$0.00 |
$8.54 M |
$14.25 M |
-$6.32 M |
$60.27 M |
-$1.30 M |
$2.52 M |
-$746,000.00 |
-$2.79 M |
-$165,000.00 |
| Operating Expenses |
$154.13 M |
$141.36 M |
$129.85 M |
$132.39 M |
$131.96 M |
$115.61 M |
$94.33 M |
$88.50 M |
$84.04 M |
$68.80 M |
| Cost And Expenses |
$447.41 M |
$391.49 M |
$367.88 M |
$338.89 M |
$322.40 M |
$303.29 M |
$243.71 M |
$239.47 M |
$258.21 M |
$228.01 M |
| Interest Income |
$5.46 M |
$1.32 M |
$601,000.00 |
$642,000.00 |
$997,000.00 |
$456,000.00 |
$425,000.00 |
$270,000.00 |
$315,000.00 |
$243,000.00 |
| Interest Expense |
$27.16 M |
$1.85 M |
$885,000.00 |
$374,000.00 |
$119,000.00 |
$243,000.00 |
$826,000.00 |
$1.02 M |
$987,000.00 |
$609,000.00 |
| Depreciation &
Amortization |
$41.78 M
|
$28.74 M
|
$26.75 M
|
$25.18 M
|
$21.12 M
|
$16.52 M
|
$15.81 M
|
$14.56 M
|
$13.25 M
|
$14.45 M
|
| EBITDA |
$241.46 M
|
$107.50 M
|
$111.78 M
|
$30.19 M
|
$81.47 M
|
$6.83 M
|
$11.90 M
|
$30.53 M
|
$3.88 M
|
-$3.09 M
|
| EBITDA Ratio |
0.37 |
0.22 |
0.16 |
0.03 |
-0 |
-0.03 |
-0.03 |
0.06 |
0.02 |
-0.08 |
| Operating Income Ratio
|
0.31
|
0.16
|
0.1
|
-0.04
|
-0
|
-0.03
|
-0
|
0.06
|
-0.03
|
-0.09
|
| Total Other
Income/Expenses Net |
-$25.63 M
|
$8.54 M
|
$14.25 M
|
-$6.32 M
|
$60.27 M
|
-$1.30 M
|
$2.52 M
|
-$746,000.00
|
-$3.47 M
|
-$165,000.00
|
| Income Before Tax |
$171.36 M |
$116.04 M |
$84.14 M |
$4.64 M |
$60.23 M |
-$9.93 M |
$1.62 M |
$14.95 M |
-$10.36 M |
-$18.15 M |
| Income Before Tax Ratio
|
0.27
|
0.23
|
0.19
|
0.01
|
0.19
|
-0.03
|
0.01
|
0.06
|
-0.04
|
-0.09
|
| Income Tax Expense |
$31.83 M |
$23.48 M |
$20.63 M |
$3.54 M |
$13.72 M |
-$3.27 M |
-$2.89 M |
$4.41 M |
-$7.58 M |
-$7.45 M |
| Net Income |
$137.55 M |
$91.39 M |
$62.12 M |
$1.10 M |
$48.94 M |
-$5.74 M |
$4.51 M |
$10.53 M |
-$2.79 M |
-$10.70 M |
| Net Income Ratio |
0.21 |
0.18 |
0.14 |
0 |
0.15 |
-0.02 |
0.02 |
0.04 |
-0.01 |
-0.05 |
| EPS |
2.85 |
1.88 |
1.3 |
0.0233 |
1.04 |
-0.12 |
0.1 |
0.23 |
-0.062 |
-0.25 |
| EPS Diluted |
2.6 |
1.74 |
1.25 |
0.0223 |
0.98 |
-0.12 |
0.09 |
0.22 |
-0.062 |
-0.25 |
| Weighted Average Shares
Out |
$48.27 M
|
$48.55 M
|
$47.78 M
|
$47.04 M
|
$46.98 M
|
$46.40 M
|
$46.11 M
|
$45.38 M
|
$44.96 M
|
$41.96 M
|
| Weighted Average Shares
Out Diluted |
$53.00 M
|
$52.43 M
|
$49.78 M
|
$49.12 M
|
$49.91 M
|
$46.40 M
|
$48.37 M
|
$47.50 M
|
$44.96 M
|
$41.96 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
